文献速递淋巴瘤白血病

Bruton酪氨酸激酶(BTK)A428D突变使慢性淋巴细胞白血病对BTK降解剂治疗产生耐药

Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia.
PubMed 文献 · Leukemia · 2024-07-24

该研究报道了慢性淋巴细胞白血病(CLL)患者在接受BTK降解剂BGB-16673临床试验期间出现BTK激酶域A428D突变,导致疾病耐药。模型分析提示该突变位于NX-2127结合口袋,可能同样导致对NX-2127耐药,而携带该突变的CLL细胞已知对共价及非共价BTK抑制剂均耐药。

要点

  • BTK A428D突变可在BGB-16673治疗期间出现并导致CLL耐药。
  • 模型提示BTK A428D突变可能使CLL对NX-2127也耐药。
  • 携带BTK A428D的CLL细胞已知对共价和非共价BTK抑制剂耐药。

核心结论

  • 临床证据表明BTK激酶域A428D突变可导致CLL对正在临床试验中的BTK降解剂BGB-16673产生耐药。
  • 模型分析提示BTK A428D突变可能使CLL细胞对另一种BTK降解剂NX-2127也耐药,且这些细胞已知对共价和非共价BTK抑制剂耐药。

研究设计与样本

  • 原文为临床证据报道,呈现一例(或若干例)接受BTK降解剂BGB-16673治疗的CLL患者出现BTK A428D突变并耐药,具体样本量原文未报告。

主要发现

  • 接受BTK降解剂BGB-16673治疗的CLL患者中出现BTK激酶域A428D突变,该突变与疾病耐药相关。
  • 对BTK A428D突变的结构建模显示,带负电荷的天冬氨酸替代了丙氨酸的疏水侧链,位于另一种BTK降解剂NX-2127的结合口袋内,提示携带该突变的CLL细胞可能对NX-2127也耐药。
  • 携带BTK A428D突变的CLL细胞已知对共价和非共价BTK抑制剂均耐药。

局限性

  • 原文为临床证据报道,具体样本量原文未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeting BTK has profoundly changed the face of CLL treatment over the past decade. Iterative advances in the cat and mouse game of resistance and redesign have moved BTK inhibitors from covalent to non-covalent and now targeted protein degraders. However, contrary to the presumption that protein degraders may be impervious to mutations in BTK, we now present clinical evidence that a mutation in the kinase domain of BTK, namely A428D, can confer disease resistance to a BTK degrader currently in clinical trials, that is BGB-16673. Modeling of a BTK A428D mutation places a negatively charged aspartic acid in place of the hydrophobic side chain of alanine within the binding pocket of another BTK-degrader in clinical development, namely NX-2127, suggesting that CLL cells with BTK A428D also may be resistant to NX-2127, as they already are known to be with either non-covalent or covalent inhibitors of BTK. Consequently, the two BTK degraders furthest advanced in clinical trials potentially may select for CLL cells with BTK A428D that are resistant to all approved BTKi's.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Wong RL, Choi MY, Wang HY, et al. Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia. Leukemia. 2024. PMID: 39048721. doi:10.1038/s41375-024-02317-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。